Business context and reporting period
Registrant mismatch: The supplied filing is for Dynamics Special Purpose Corp., not Senti Biosciences Holdings, Inc. It is a shell-company SPAC formed to pursue a business combination, not an operating biotechnology business. The unaudited reporting period is March 1, 2021 (inception) through March 31, 2021; it does not provide a comparable prior-year period.
Financial results and position
- Revenue: None. The company had not commenced operations and expected no operating revenue before a business combination.
- Profit and margins: Net loss was $1,178, entirely from formation and operating costs. Basic and diluted loss per share was reported as $(0.00). Revenue-based margins are not applicable.
- Cash flow: Net cash used in operating activities was $0; cash at March 31 was $0. The net loss was offset by related-party payment of costs and working-capital changes.
- Balance sheet and liquidity: Total assets were $373,657, all deferred offering costs. Total liabilities were $349,835, including $337,157 accrued offering costs and $11,650 due to a related party. Stockholders’ equity was $23,822. No borrowings under the sponsor promissory note were outstanding at March 31.
- Debt: No debt balance was reported at March 31. The company could borrow up to $300,000 from its sponsor under a non-interest-bearing note; it subsequently borrowed $250,000 in April and repaid it May 26, 2021.
Material changes and subsequent events
After quarter-end, on May 28, 2021, the company completed its IPO of 23,000,000 Class A shares at $10 each, including full exercise of the over-allotment option, for $230 million gross proceeds. It also sold 715,500 private-placement shares to its sponsor for $7.155 million. The filing states that $230 million was placed in the trust account. The IPO and private placement occurred after the reported balance-sheet date and are not March 31 financial balances.
Outlook, risks and contingencies
- The SPAC had until May 28, 2023 to complete a business combination; otherwise it would generally redeem public shares and liquidate. Completion was not assured.
- Management expected approximately $1.1 million of proceeds outside the trust account for search and operating costs and estimated key pre-combination expenses, while cautioning actual costs could differ materially. Additional financing might be needed.
- The sponsor or affiliates could provide working-capital loans, but were not obligated to do so; up to $2 million could be convertible into shares at the lender’s option.
- A deferred underwriting commission of $8.05 million would be payable from trust funds only if a business combination closes. The underwriter waived that commission if the company liquidates without completing one.
- Management said COVID-19 could adversely affect the company’s financial position, operations, or target search, but the impact was not determinable. No market or interest-rate risk was reported as of March 31.
- Management concluded disclosure controls were effective as of March 31, and reported no material change in internal control over financial reporting. No legal proceedings were reported; the filing disclosed no material changes to prospectus risk factors.
Most important facts to verify
- Confirm the intended filing: this 10-Q names Dynamics Special Purpose Corp., not Senti Biosciences Holdings, Inc.
- Verify the post-quarter IPO, private placement, and trust-account funding in the related subsequent filings.
- Review the SPAC’s business-combination deadline, redemption terms, financing needs, and deferred underwriting fee.
- Check the prospectus risk factors and any later disclosures regarding the COVID-19 impact or business-combination search.